Author

P. Bandopadhayay

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Research Focus:differential expression· 3 Approach:genetic perturbation / CRISPR· 3 Approach:statistical model· 3 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

K. L. Ligon· 4 shared R. Beroukhim· 3 shared D. E. Root· 2 shared A. Brown· 1 shared A. Crane· 1 shared A. Goodale· 1 shared A. Iniguez· 1 shared A. J. Church· 1 shared

Activity by Year

2018-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

K. L. Ligon

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Phenotypic screens identify biologic regulators of nanoparticle uptake in diffuse midline glioma

E. L. Cheng, S. Pal, J. W. Tsai, C. B. Yampanis, S. Rangaswamy, J. Kenny-Serrano, M. Coppola, M. Ozdemir, K. Y. Cai, E. VanGosen, E. Bateman, K. R. Bennett, M. M. Billingsley, C. A. Whittaker, Y. Zhang, , J. P. Straehla

The paper identifies biologic regulators of nanoparticle uptake in diffuse midline glioma using CRISPR screens and functional assays, finding CTNNB1 and pathway members as key modulators.

bioRxiv · Sep 11, 2026 · PreprintBioengineering

A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer

V. Rendo, M. Schubert, N. Khuu, M. F. Suarez Peredo Rodriguez, K. Huang, M. Swift, Y. He, J. Zerbib, R. Smith, J. Raaijmakers, P. Bandopadhayay, L. M. Guenther, J. H. Hwang, A. Iniguez, S. Moody, , F. Foijer

The paper identifies ARGOS genes, which are amplified in cancer, have low expression relative to copy number, and are toxic when overexpressed, and validates several as pan-cancer targets.

bioRxiv · Dec 16, 2023 · PreprintCancer Biology

Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma

D. A. Hofman, J. Ruiz-Orera, I. Yannuzzi, R. Murugesan, A. Brown, K. R. Clauser, A. L. Condurat, J. T. van Dinter, S. A. G. Engels, A. Goodale, J. van der Lugt, T. Abid, L. Wang, K. N. Zhou, J. Vogelzang, , J. R. Prensner

The paper investigates non-canonical ORF translation in medulloblastoma, identifying ASNSD1-uORF as critical for cell survival through interactions with the prefoldin-like chaperone complex.

bioRxiv · May 4, 2023Cancer Biology

Aberrant DNA repair is a vulnerability in histone H3.3-mutant brain tumors

B. Rondinelli, G. Giacomini, S. Piquet, O. Chevallier, J. Dabin, S.-K. Bai, B. Kim, R. Siddaway, B. Raught, E. Coyaud, C.-M. Shan, R. J. D. Reid, T. Toda, R. Rothstein, T. Wilhelm, , S. E. Polo

The paper identifies aberrant DNA repair as a vulnerability in H3.3-mutant brain tumors, showing that PNKP-mediated repair is specific to mutant cells and offers therapeutic potential.

bioRxiv · Sep 29, 2022 · PreprintCancer Biology

Single Cell Spatial Analysis Reveals the Topology of Immunomodulatory Purinergic Signaling in Glioblastoma

S. Coy, S. Wang, S. A. Stopka, J.-R. Lin, R. Rashid, C. Yapp, C. C. Ritch, P. Khadka, M. Regan, J. Hwang, P. Y. Wen, P. Bandopadhayay, K. L. Ligon, N. Y. Agar, P. K. Sorger, , S. Santagata

The paper uses spatial single-cell analysis to show that CD73 and CD39 expression in glioblastoma correlates with poor clinical outcomes and immunosuppressive signaling.

bioRxiv · Jan 12, 2022Cancer Biology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology